Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Psyence BiomedicalPBM +9.64%14 Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus rates PBM with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 304 Biotechnology companies, Psyence Biomedical ranks worse than 328947.04% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Psyence Biomedical's Debt-to-EBITDA or its related term are showing as below:
PBM's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.215 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Psyence Biomedical Debt-to-EBITDA Related Terms
Psyence Biomedical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Psyence Biomedical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBM vs NRSN, PLUR, CALC: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Psyence Biomedical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Psyence Biomedical Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Psyence Biomedical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Psyence Biomedical (PBM) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Psyence Biomedical. According to the industry distribution chart, Psyence Biomedical ranks #999999 out of 304 companies in the Biotechnology industry.
Is Psyence Biomedical's Debt-to-EBITDA too high?
Psyence Biomedical's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Psyence Biomedical ranks #999999 out of 304 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Psyence Biomedical has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Psyence Biomedical's Debt-to-EBITDA compare to NRSN and PLUR?
According to the Biotechnology industry distribution chart, Psyence Biomedical ranks #999999 out of 304 companies for Debt-to-EBITDA. This places Psyence Biomedical in the lower half of its industry. The industry median Debt-to-EBITDA is 1.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.22, based on 304 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Psyence Biomedical. For the Biotechnology industry, the median Debt-to-EBITDA is 1.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Psyence Biomedical's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psyence Biomedical stock overvalued right now?
Psyence Biomedical (PBM) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Psyence Biomedical's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Psyence Biomedical (PBM), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
14GF Score
Get the complete analysis for PBM
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBM has been successfully added to your 
